ACTIVE

Pharmacie YSER

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result104,4 k €+27,8 %over 1 year
Gross margin361 k €+19,1 %over 1 year
Equity403,7 k €+34,9 %over 1 year
Workforce2,9 ETP-3,3 %over 1 year

Identity

Source · BCE/KBO

Pharmacie YSER is a Private limited company incorporated in 2004. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Bruxelles. It employs on average 2,9 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0864.899.312
Incorporation
23/04/2004
Legal form
Private limited company
Registered office
Chaussée d'Anvers 52
1000 Bruxelles · BruxellesSee on map
Contributed capital
22 100,00 €
Latest accounts
31/12/2025
Average workforce
2,9 ETP
Joint committees (1)
  • 313
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 21 filings

Trend over 20 financial years

20252024202320222021
Income statement
Gross margin361 k €303,2 k €236,2 k €266,9 k €311,7 k €
EBITDA195,4 k €140,5 k €92,3 k €162,5 k €174 k €
Operating result153,4 k €117,7 k €74,4 k €144,7 k €156 k €
Net result104,4 k €81,7 k €49,8 k €105,1 k €141,9 k €
Balance sheet
Equity403,7 k €299,3 k €217,6 k €167,8 k €62,7 k €
Total assets808,1 k €753,5 k €609,8 k €575,5 k €559,3 k €
Cash7,3 k €2,8 k €21,6 k €44 k €12,6 k €
Debts404,4 k €454,2 k €389,6 k €407,8 k €496,6 k €
Other
Workforce2,9 ETP3,0 ETP3,0 ETP2,2 ETP2,6 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 10 ended

Active mandates

GROUPE TETE PHARMACEUTICAL

Manager · since 03 janvier 2014 · 0542.600.182

Represented by Kwassigan TETE

Active
Kwassigan TETE

Director · since 03 janvier 2014

Active

Ended mandates

GROUPE TETE PHARMACEUTICAL

Manager · since 03 janvier 2014 · 0542.600.182

Represented by Richard BONTEMPS

Ended
GROUPE TETE PHARMACEUTICAL

Director · since 03 janvier 2014 · 0542.600.182

Represented by Kwassigan TETE

Ended
GROUPE TETE PHARMACEUTICAL

Manager · since 03 janvier 2014 · 0542.600.182

Represented by Richard BONTEMPS

Ended
GROUPE TETE PHARMACEUTICAL

Director · since 03 janvier 2014 · 0542.600.182

Represented by Kwassigan TETE

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date05/08/202620/08/202521/08/202401/07/202301/09/202230/08/2021
General meeting04/05/202605/05/202506/05/202408/05/202302/05/202227/08/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 21 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202504/05/202605/08/2026FrenchPDF
Abridged model31/12/202405/05/202520/08/2025FrenchPDF
Abridged model31/12/202306/05/202421/08/2024FrenchPDF
Abridged model31/12/202208/05/202301/07/2023FrenchPDF
Abridged model31/12/202102/05/202201/09/2022FrenchPDF
Abridged modelCorrection31/12/202027/08/202130/08/2021FrenchPDF
Abridged model31/12/202003/05/202128/06/2021FrenchPDF
Abridged model31/12/201904/05/202030/06/2020FrenchPDF
Abridged model31/12/201806/05/201905/07/2019FrenchPDF
Abridged model31/12/201707/05/201829/06/2018FrenchPDF
Abridged model31/12/201608/05/201730/06/2017FrenchPDF
Abridged model31/12/201502/05/201620/07/2016FrenchPDF
Abridged model31/12/201404/05/201528/07/2015FrenchPDF
Abridged model31/12/201304/05/201403/07/2014FrenchPDF
Abridged model31/12/201226/05/201317/06/2013FrenchPDF
Abridged model31/12/201130/06/201231/07/2012FrenchPDF
Abridged model31/12/201030/06/201128/07/2011DutchPDF
Abridged model31/12/200921/05/201010/06/2010DutchPDF
Abridged model31/12/200802/06/200930/06/2009DutchPDF
Abridged model31/12/200723/05/200817/06/2008FrenchPDF
Abridged model31/12/200627/05/200726/06/2007DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 10 ended

Active mandates

GROUPE TETE PHARMACEUTICAL

Manager · since 03 janvier 2014 · 0542.600.182

Represented by Kwassigan TETE

Active
Kwassigan TETE

Director · since 03 janvier 2014

Active

Ended mandates

GROUPE TETE PHARMACEUTICAL

Manager · since 03 janvier 2014 · 0542.600.182

Represented by Richard BONTEMPS

Ended
GROUPE TETE PHARMACEUTICAL

Director · since 03 janvier 2014 · 0542.600.182

Represented by Kwassigan TETE

Ended
GROUPE TETE PHARMACEUTICAL

Manager · since 03 janvier 2014 · 0542.600.182

Represented by Richard BONTEMPS

Ended
GROUPE TETE PHARMACEUTICAL

Director · since 03 janvier 2014 · 0542.600.182

Represented by Kwassigan TETE

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates13/02/2025
    MODIFICATION FORME JURIDIQUE - DEMISSIONS, NOMINATIONS
    PDF
  • Mandates22/03/2024
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates28/03/2023
    DEMISSIONS, NOMINATIONS - MODIFICATION FORME JURIDIQUE
    PDF
  • Mandates05/02/2014
    SIEGE SOCIAL - DEMISSIONS, NOMINATIONS
    PDF
  • Mandates08/01/2014
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates21/12/2010
    DENOMINATION - ADRESSE AUTRE QUE SIEGE SOCIAL - OBJET - CAPITAL, ACTIONS
    PDF
  • Registered office17/03/2009
    SIEGE SOCIAL
    PDF
  • Mandates06/09/2006
    DEMISSIONS, NOMINATIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025104,4 k €↑
  2. 2024
    Annual accounts 202481,7 k €↑
  3. 2023
    Annual accounts 202349,8 k €↓
  4. 2022
    Annual accounts 2022105,1 k €↓
  5. 2021
    Annual accounts 2021141,9 k €↑
  6. 2020
    Annual accounts 2020-20,6 k €↓
  7. 2019
    Annual accounts 201926,5 k €↑
  8. 2018
    Annual accounts 2018-48,6 k €↑
  9. 2017
    Annual accounts 2017-78,6 k €↓
  10. 2016
    Annual accounts 201617,1 k €↓
  11. 2015
    Annual accounts 201528,7 k €↑
  12. 2014
    Annual accounts 201414 k €↓
  13. 2013
    Annual accounts 201316,8 k €↓
  14. 2012
    Annual accounts 201226,8 k €↑
  15. 2011
    Annual accounts 2011-27,4 k €↓
  16. 2010
    Annual accounts 2010-17,8 k €↓
  17. 2009
    Annual accounts 2009-5,5 k €↓
  18. 2008
    Annual accounts 200842,3 k €↓
  19. 2007
    Annual accounts 2007137,2 k €↑
  20. 2006
    Annual accounts 200659 k €
  21. 23/04/2004
    IncorporationPrivate limited company